FDA announced a Public Advisory Committee Meeting to review the approval of flibanserin for hypoactive sexual desire disorder (HSDD) in women on June 4, 2015. Should you wish to submit your written comments or request time at the public microphone, the deadline is a week away. Please find all details in the Federal Register Notice by clicking on this link. - -